Amortization of Deferred Income

No definition available.

Name:	bmy_AmortizationofDeferredIncome
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents royalty income recognized in other income during the period related to the sale of a business.

+ References

No definition available.

+ Details

Name:	bmy_BusinessSaleRoyaltyIncome
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of net sales of certain products in certain territories payable as a distribution fee pursuant to the collaboration agreement to other collaboration partners.

+ References

No definition available.

+ Details

Name:	bmy_CollaborationDistributionFeePercentage
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

This element represents the total contingent approval milestone payments to potentially be received as consideration for the sale of a business.

+ References

No definition available.

+ Details

Name:	bmy_ContingentApprovalMilestones
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents the maximum contingent proceeds to be received if and when the transfer of certain assets and businesses related to the sale of a business occur.

+ References

No definition available.

+ Details

Name:	bmy_ContingentPaymentsRelatedToTransferOfCertainAssetsAndBusinesses
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This represents the amount of gains and royalties as a result of business divestitures.

+ References

No definition available.

+ Details

Name:	bmy_Divestituregainsandroyalties
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Initial divestiture proceeds that was received in the first quarter of 2018.

+ References

No definition available.

+ Details

Name:	bmy_InitialdivestitureproceedsreceivedinQ12018
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone Earned from Divestiture Business

+ References

No definition available.

+ Details

Name:	bmy_MilestoneEarnedfromDivestitureBusiness
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Ownership Interest

+ References

No definition available.

+ Details

Name:	bmy_OwnershipInterest
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

percentage of net sales payable to alliance partner

+ References

No definition available.

+ Details

Name:	bmy_Percentageofnetsalespayabletoalliancepartner
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents the approximate percentage of potential future royalties that were transferred to a third party.

+ References

No definition available.

+ Details

Name:	bmy_Percentageofpotentialfutureroyaltiestransferred
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents the cash proceeds received at closing related to the sale of a business.

+ References

No definition available.

+ Details

Name:	bmy_ProceedsReceivedAtClosingForSaleOfBusiness
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents a payment to be received from an alliance partner as consideration for restructuring an alliance agreement.

+ References

No definition available.

+ Details

Name:	bmy_TerminalPayment
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents the total contingent development and regulatory milestone payments to be potentially received as consideration for the sale of a business.

+ References

No definition available.

+ Details

Name:	bmy_TotalContingentDevelopmentandRegulatoryMilestonePayments
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents the total contingent regulatory and sales-based milestone payments to potentially be received as consideration for the sale of a business.

+ References

No definition available.

+ Details

Name:	bmy_TotalContingentRegulatoryandSalesBasedMilestonePayments
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents the total contingent sales-based milestone payments to potentially be received as consideration for the sale of a business.

+ References

No definition available.

+ Details

Name:	bmy_TotalContingentSalesBasedMilestones
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents the amount of transition and other fees earned related to transitional services performed.

+ References

No definition available.

+ Details

Name:	bmy_Transitionfees
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of upfront payment received as a result of a business divestiture.

+ References

No definition available.

+ Details

Name:	bmy_Upfrontpaymentreceived
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228

+ Details

Name:	us-gaap_AssetImpairmentCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

+ Details

Name:	us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of Equity in net profit and loss for the period. Give totals for each group. If operations of any controlled companies are different in character from those of the company, group such affiliates (1) within divisions and (2) by type of activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column C))
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(2))
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(6))
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

+ Details

Name:	us-gaap_InvestmentsInAndAdvancesToAffiliatesAmountOfEquity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

This element represents the cash inflow during the period from the sale of a component of the entity.

+ References

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromRoyaltiesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_DiabetesbusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_ErbituxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_ManufacturingFacilityinSwordsIrelandMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_AvaproAvalideAndPlavixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_InvestigationalHIVbusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_OverthecounterproductsReckittMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_OtherdivestituresMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_CPPIBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_ReckittBenckiserGroupMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_MaturebrandCheplapharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_NotallinclusiveMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=bmy_AmylinRelatedProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=bmy_AvaproAvalideAndPlavixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=bmy_ErbituxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_LillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_LillyAndMerckKgaaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=bmy_TerritoryCoveringEuropeAndAsiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=bmy_TerritoryCoveringAmericasAndAustraliaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=bmy_OnglyzaandFarxigaProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=bmy_UnitedStatesJapanandEUMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=bmy_SprycelAndIxempraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredRevenueArrangementTypeDomain
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LocationAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

DIVESTITURES (Details) - USD ($) $ in Millions	12 Months Ended
DIVESTITURES (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	$ 1,247	$ 651	$ 1,317
Divestiture gain	178	164	576
Royalties	(814)	(557)	(618)
Proceeds from Divestiture of Businesses	992	706	1,187
Asset impairment charges	64
Diabetes business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	579	405	333
Divestiture gain	0	(126)	0
Royalties	(661)	(329)	(361)
Erbitux [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	216	218	252
Divestiture gain	0	0	0
Royalties	(145)	(224)	(246)
Manufacturing Facility in Swords, Ireland [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	160	0	0
Divestiture gain	0	0	0
Royalties	0	0	0
Initial divestiture proceeds received in Q1 2018		158
Asset impairment charges		146
Avapro, Avalide, and Plavix [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	80	0	0
Divestiture gain	0	0	0
Royalties	0	0	0
Investigational HIV business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	0	0	387
Divestiture gain	0	(11)	(272)
Royalties	0	0	0
Total contingent sales based milestones		4,300
Upfront payment received		350
Total Contingent Development and Regulatory Milestone Payments		1,100
Transition fees		10	105
Over the counter products - Reckitt [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	0	0	317
Divestiture gain	0	0	(277)
Royalties	0	0	0
Proceeds from Divestiture of Businesses			277
Other divestitures [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	212	28	28
Divestiture gain	(178)	(24)	(15)
Royalties	(8)	(4)	(11)
AstraZeneca [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds Received At Closing For Sale Of Business					$ 2,700
Total Contingent Regulatory and Sales Based Milestone Payments	1,400
Contingent Approval Milestones	800
Total contingent sales based milestones	600
Contingent Payments Related To Transfer Of Certain Assets And Businesses	225
Milestone Earned from Divestiture Business		100
Amortization of Deferred Income			113
Proceeds from Royalties Received	457	229	227
CPPIB [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Royalties Received	45	100	134
Royalty Pharma [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Royalties Received	159
Reckitt Benckiser Group [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses			317
Mature brand, Cheplapharm [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture gain	(127)
Proceeds from Divestiture of Businesses	153
Not all inclusive [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture gain	(178)	(161)	(564)
Amylin Related Products [Member] \| CPPIB [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of potential future royalties transferred				70.00%
Avapro, Avalide, and Plavix [Member] \| Sanofi [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Terminal Payment	200
North America [Member] \| Erbitux [Member] \| Lilly [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalties	145	207	227
JAPAN \| Erbitux [Member] \| Lilly and Merck KGaA [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalties		17	19
Territory Covering Europe and Asia [Member] \| Avapro, Avalide, and Plavix [Member] \| Sanofi [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Investments in and Advances to Affiliates, Amount of Equity	$ 96	95	95
Ownership Interest	49.90%
Territory Covering Americas and Australia [Member] \| Avapro, Avalide, and Plavix [Member] \| Sanofi [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Royalties Received	$ 26	$ 200	$ 195
Minimum [Member] \| Onglyza and Farxiga Products [Member] \| Royalty Pharma [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of potential future royalties transferred		20.00%
Minimum [Member] \| United States, Japan and EU [Member] \| Sprycel and Ixempra [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
percentage of net sales payable to alliance partner	10.00%
Maximum [Member] \| Onglyza and Farxiga Products [Member] \| Royalty Pharma [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of potential future royalties transferred		25.00%
Maximum [Member] \| United States, Japan and EU [Member] \| Sprycel and Ixempra [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
percentage of net sales payable to alliance partner	25.00%
Scenario, Plan [Member] \| Manufacturing Facility in Swords, Ireland [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds		$ 165
Deferred Revenue [Domain] \| Territory Covering Europe and Asia [Member] \| Avapro, Avalide, and Plavix [Member] \| Sanofi [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses	$ 80
Other Current Assets [Member] \| Territory Covering Europe and Asia [Member] \| Avapro, Avalide, and Plavix [Member] \| Sanofi [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses	$ 120
North America [Member] \| Erbitux [Member] \| Lilly [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Collaboration Distribution Fee Percentage		39.00%